Biobank-scale characterization of Alzheimer’s disease and related dementias identifies potential disease-causing variants, risk factors, and genetic modifiers across diverse ancestries

Discovery phase: UK Biobank

The UK Biobank (UKB) (https://www.ukbiobank.ac.uk/) is a large-scale biomedical dataset containing detailed genetic, clinical, and lifestyle information from over 500,000 participants aged 40 to 69 years in the United Kingdom. Each participant’s profile includes a diverse array of phenotypic and health-related information. Additionally, the participants’ health has been followed long-term, primarily through linkage to a wide range of health-related records, enabling the validation and characterization of health-related outcomes [7]. This dataset has been instrumental in advancing research on various health conditions, including AD/ADRDs, by facilitating large- scale genome-wide association studies and rare, deleterious variant analyses [7].

Discovery phase: 100,000 Genomes Project

The 100,000 Genomes Project (100KGP) (https://www.genomicsengland.co.uk/) has sequenced and analyzed genomes from over 75,000 participants with rare diseases and family members. Early onset dementia (encompassing FTD) is one of the rare diseases studied by the Neurology and Neurodevelopmental Disorders group within the rare disease domain. Participants were recruited by healthcare professionals and researchers from 13 Genomic Medicine Centres in England. The probands were enrolled in the project if they or their guardian provided written consent for their samples and data to be used in research. Probands and, if feasible, other family members were enrolled according to eligibility criteria set for certain rare disease conditions.

WGS data were utilized from 180 unrelated cases with early-onset dementia (encompassing FTD and prion disease) or Parkinson’s disease (PD) with dementia phenotype and 3,479 unrelated controls ≥ 65 years at the time of the analysis. Sequencing and quality control analyses for the 100KGP were previously described elsewhere [26] (https://re-docs.genomicsengland.co.uk/sample_qc/). Protein-altering or splicing variants were obtained using the Exomiser variant prioritization application [27]. Candidate variants were extracted from a multi-sample aggregated VCF provided in the Genomics England research environment.

Replication phase: Alzheimer’s Disease Sequencing Project

The Alzheimer’s Disease Sequencing Project (ADSP) (https://adsp.niagads.org/), supported by the National Institute on Aging and the National Human Genome Research Institute, aims to generate data associated with AD/ADRDs. This dataset includes genetic data from thousands of individuals with and without AD, facilitating the discovery of novel genetic risk factors and pathways underlying the disease.

We used data from the ADSP dataset (v4) for this study, which included a total of 10,566 AD cases and 16,217 controls. The control cohort includes individuals ≥ 65 years without any neurological condition or family history of neurological disorders. Samples were excluded from further analysis if the sample call rate was less than 95%, the genetically determined sex did not match the sex reported in clinical data, or excess heterozygosity was detected (|F| statistics > 0.25). For quality control purposes, an MAF threshold of 0.1% was used. The missingness rate and allele frequency of these variants were calculated for each ancestry using PLINK v2.0 [21] and PLINK v1.9 [28]. Variant quality control included removing variants with Hardy-Weinberg Equilibrium P < 1 × 10⁻⁴ in control samples, differential missingness by case-control status at P ≤ 1 × 10⁻⁴, and non-random missingness by haplotype at P ≤ 1 × 10⁻⁴. Relatedness was calculated with KING [22], and individuals closer than cousins were removed by KINSHIP > 0.0884. Duplicated samples were also removed. ADSP includes a range of cohorts, including extensive family cohorts and cohorts with progressive supranuclear palsy (PSP), corticobasal degeneration, mild cognitive impairment (MCI), and DLB patients. Only samples labeled as definite AD or control were included in this analysis. We meticulously screened for identified genetic variants with a CADD score > 20 that were present across any of the three discovery datasets (AoU, 100KGP, and UKB) in the ADSP cohort.

Replication phase: Accelerating Medicines Partnership in Parkinson’s Disease

Accelerating Medicines Partnership (AMP) (https://fnih.org/our-programs/accelerating-medicines-partnership-amp/) is a public-private initiative that aims to transform the current model for developing new diagnostics and treatments by jointly identifying and validating promising biological targets for therapeutics. It was launched in 2014 by the NIH, the U.S. Food and Drug Administration, multiple biopharmaceutical and life science companies, and several non-profit organizations. AMP PD focuses on advancing research into PD-related disorders and leverages cutting-edge technologies and large-scale data analysis to identify key genetic variants, biomarkers, and therapeutic targets associated with PD-related disorders, with the ultimate goal of developing novel treatments and improving patient outcomes.

We used AMP PD Release 3 genomic data, focusing specifically on DLB cases and controls. Samples were excluded from further analysis if the sample call rate was less than 95%, the genetically determined sex did not match the sex reported in clinical data, or excess heterozygosity was detected (|F| statistics > 0.25). Variant quality control included removing variants with missingness above 0.05%. Relatedness was calculated with KING [22], and individuals closer than first cousins were removed by KINSHIP > 0.0884. After quality control and ancestry prediction, this dataset contains a total of 2,530 DLB cases and 3,270 controls, characterized as individuals ≥ 65 years without any neurological condition or family history of any neurological disorders. We screened for identified variants with a CADD score > 20 that were present across all three discovery datasets (AoU, 100KGP, and UKB) within AMP PD. Allele frequency of these variants per ancestry was calculated using PLINK v2.0 [21] and PLINK v1.9 [28].

Ancestry Prediction Analysis

All samples in AoU, UKB, ADSP, and AMP PD datasets underwent a custom ancestry prediction pipeline included in the GenoTools package (https://github.com/dvitale199/GenoTools) [29]. In brief, ancestry was defined using reference panels from the 1000 Genomes Project, the Human Genome Diversity Project, and an Ashkenazi Jewish population dataset. We used a panel of 4,008 samples from 1000 Genomes Project and the Gene Expression Omnibus database (www.ncbi.nlm.nih.gov/geo; accession no. GSE23636) to define ancestry reference populations. The reference panel was then reduced to exclude palindromic SNPs (AT or TA or GC or CG). SNPs with minor allele frequency (MAF) < 0.05, genotyping call rate < 0.99, and HWE P < 1E-4 in the reference panel were further excluded. Variants overlapping between the reference panel SNP set and the samples of interest were then extracted. Any missing genotypes were imputed using the mean of that particular variant in the reference panel. The reference panel samples were split into an 80/20 train/test set, and then PCs were fitted using the set of overlapping SNPs described previously. The PCs were then transformed via UMAP to represent global genetic population substructure and stochastic variation. A classifier was then trained on these UMAP transformations of the PCs (linear support vector). Based on the test data from the reference panel and at 5-fold cross-validation, 11 ancestries were predicted consistently with balanced accuracies greater than 0.95.

Genetic ancestry in 100KGP was estimated by generating PCs for 1000 Genomes Project phase 3 samples and projecting all participants onto the super populations in the 1000 Genomes Project, as described elsewhere (https://re-docs.genomicsengland.co.uk/ancestry_inference/). Despite our efforts to utilize GenoTools, we encountered significant challenges during its implementation in Genomics England’s High-Performance Computing Cluster (HPC). Consequently, GenoTools and Genomics England’s HPC were incompatible in this context. PCA plots across all biobanks are shown in Supplementary Figure 1.

Evaluation of potential disease-causing mutations, risk factors, and disease risk modifiers across ancestries

In the discovery phase, variants were filtered out based on their presence in control individuals across biobanks. To prioritize potential disease-causing mutations, we followed the American College of Medical Genetics and Genomics (ACMG) guidelines (https://wintervar.wglab.org/), leveraging existing clinical and population databases and pathogenicity predictors including the Human Gene Mutation Database (HGMD) (https://www.hgmd.cf.ac.uk/ac/index.php), dbSNP (https://www.ncbi.nlm.nih.gov/snp/), gnomAD (https://gnomad.broadinstitute.org/), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), and Combined Annotation Dependent Depletion (CADD) scores (GRCh38-v1.7) (https://cadd.gs.washington.edu/).

Secondly, we investigated APOE, the major risk factor for AD/ADRDs, across diverse ancestries. We used PLINK (v1.9 and v2.0) [21,28] to extract genotypes for two APOE variants, rs429358 (chr19:44908684-44908685) and rs7412 (chr19:44908821-44908823), as a proxy for APOE allele status (ε1, ε2, ε3, and ε4) in the AoU, UKB, ADSP, and AMP PD datasets. Data analysis was conducted as reported elsewhere (https://github.com/neurogenetics/APOE_genotypes). In the 100KGP dataset, APOE genotypes were analyzed using PLINK v2.0 [21] in a multi-sample aggregated VCF provided in the Genomics England research environment. Subsequently, we calculated the number of individuals with each genotype per ancestry and their frequency percentages.

Finally, we assessed disease modifiers for APOE ε4 homozygous and heterozygous carriers specifically. A total of 21 variants, previously identified as either protective (n=11) or resilient (n=10), were extracted from all datasets using the same protocol previously described. Among them, ABCA7:rs72973581-A, APP:rs466433-G, APP:rs364048-C, NOCT:rs13116075-G, SORL1:rs11218343-C, SLC24A4:rs12881735-C, CASS4:rs6024870-A, EPHA1:rs11762262-A, SPPL2A:rs59685680-G, APP:rs63750847-T, PLCG2:rs72824905-G are protective, while 19q13.31:rs10423769-A, APOE:rs449647-T, FN1:rs140926439-T, FN1:rs116558455-A, RELN:rs201731543-C, TOMM40:rs11556505-T, RAB10:rs142787485-G, LRRC37A:rs2732703-G, NFIC:rs9749589-A, and the APOE3 Christchurch:rs121918393-A variant are reported to be resilient. These variants were then checked across all APOE genotypes and ancestries. Carrier frequencies (either heterozygous or homozygous) were calculated for each APOE genotype and ancestry and were then combined across each of the datasets. In AoU, a variant dataset in Hail format (WGS_VDS_PATH) was used for the analysis. PLINK v2.0 [21] and R v4.3.1 (https://www.r-project.org/) were used to assess the protective model (which evaluates the effect of each protective/disease-modifying variant on the phenotype), conditional model (which evaluates the effect of each protective/disease-modifying variant on the phenotype in the presence of APOE (ε4, ε4/ε4, ε3/ε3)), R² model (which evaluates the correlation of each protective/disease- modifying variant with APOE (ε4, ε4/ε4, ε3/ε3)), and interaction model (which evaluates putative interactions between each protective/disease-modifying variant and APOE (ε4, ε4/ε4, ε3/ε3) on the phenotype). Logistic and linear regression analyses, adjusting for APOE status, sex, age, and PCs, were applied in the most well-powered dataset (ADSP) to explore these effects.

Replication analyses support the relevance of identified genetic variation across diverse ancestries

Six variants identified in AoU, 16 identified in UKB, and three identified in 100KGP were replicated in AD cases in the ADSP cohort (Table 3). Among the six variants found in AoU that were replicated in ADSP, two variants — APP p.A713T and PSEN1 p.A79V — had been previously reported, while four variants — APP p.L597W, MAPT p.G701R, MAPT p.G750S, and SNCA p.Q99R — were novel, with APP p.L597W being found in African, African Admixed, and Complex Admixture History ancestries. Searching for other dementia cases resulted in the identification of APP p.A713T in one DLB case and PSEN1 p.A79V in a possible AD case according to ADSP diagnosis criteria. The allele frequency of each variant per genetic ancestry in cases and controls is reported in Table 3.

Among the three variants identified in the 100KGP dataset that were replicated in the ADSP cohort, PSEN1 p.R269H was previously reported while PSEN2 p.D320N and APP p.Y407H were novel. We observed the previously reported PSEN1 p.R269H variant in five cases and no control participants. This variant was found in European ancestry individuals from the 100KGP cohort and was also observed in individuals of African Admixed ancestry (two cases) and European ancestry (three cases) in the ADSP dataset. Of the novel variants, the PSEN2 p.D320N variant was found in five controls and was not observed in any cases, while the APP p.Y407H variant was observed in two cases and one control. Searching for additional cases led to the discovery of PSEN1 p.R269H in a patient with MCI.

Among the 16 variants identified in the UKB cohort that were replicated in the ADSP dataset, five variants — PSEN1 p.A79V (five cases and one control), PSEN1 p.R269H (five cases), GRN p.R493X (three cases), MAPT p.R406W (four cases and one control), and GBA1 p.W223R (one case and one control) — have been previously reported. The remaining 11 variants were novel. Most of the novel variants were found in European cases in the UKB. The PSEN1 p.R269H variant was found in cases of both African Admixed and European ancestries, and GBA1 p.W223R was found in a case of Complex Admixture History ancestry and a control of African ancestry. The three remaining known variants were observed in individuals of European ancestry in the ADSP cohort. Novel variants identified in non-European participants include PSEN1 p.R220Q (one African case, two European cases, and one African Admixed control), PSEN1 p.T291A (one African Admixed case, one American Admixed control, and two controls with Complex Admixture History), MAPT p.A60G (two African Admixed cases, one African Admixed control, two African controls, and four controls with Complex Admixture History), GRN p.V490M (one African Admixed case), MAPT p.R103W (one American Admixed control), and APP p.P251S (one South Asian control). Searching for other cases resulted in the identification of PSEN1 p.A79V in one possible AD patient, PSEN1 p.R269H and MAPT p.A60G in two independent MCI patients, and GBA1 p.W223R and APP p.A209T in two independent PSP patients (Table 3).

We identified a novel SNCA variant (p.Q99R) in the AoU dataset, while the UKB dataset revealed two additional variants in SNCA: p.P90H and p.A91S. Both p.P90H and p.A91S were predicted to be likely pathogenic according to prediction estimates and have not been previously reported as disease-causing. Notably, the SNCA p.Q99R variant was replicated in the ADSP cohort. All three variants were heterozygous, and none of these variants were found in any controls across these datasets. However, the age at onset of these variant carriers is not consistent with a potential disease-causing deleterious effect.

Our analyses of multiple datasets identified 11 variants (three from AoU, seven from UKB, and one from 100KGP) that were absent in the ADSP control cohort.

Across each of our discovery datasets, we identified five candidate variants — APP p.A713T, MAPT p.G750S, GRN p.V490M, GRN p.R493X, and APP p.D516N — present in AMP PD. GRN p.V490M was present in one control and no cases, GRN p.R493X was present in one case and no controls, while the other three were present across both cases and controls. The allele frequencies of these variants are detailed in Table 4.

Among the 116 variants identified in this study, 13 were found exclusively in non-European ancestries. Notably, APP:p.L597W and MAPT:p.A60G were replicated in African and African Admixed ancestries across different datasets. These data highlight the potential significance of these variants in groups that are often underrepresented in genomic studies.

Supplementary Figure 2 shows the allele frequencies of all identified known and novel variants with CADD > 20 in the discovery and replication phases across all ancestries in each biobank.

Previously reported disease-causing variants raise questions about potential pathogenicity

Although the SNCA p.H50Q variant was initially identified as a pathogenic mutation in PD [30], subsequent research has challenged its pathogenicity [31]. Our study confirms that it is not pathogenic across other synucleinopathies such as DLB, based on its occurrence in five European controls in AoU and 28 European controls in UKB.

Additionally, several research studies have reported the APP p.A713T variant to be disease- causing [32,33]. In our study, we found this variant in heterozygous state in five control individuals: two in UKB, two in ADSP, and one in AMP PD. Interestingly, the APP p.E665D variant, which has been widely reported to cause AD [34,35], was found in one control in AoU in her late 70s. However, it is possible that the variant shows incomplete penetrance, or that this individual may harbor unidentified resilient genetic variation. Another previous study evaluating the role of APP p.E665D questioned the pathogenicity of this variant [36].

GBA1 coding variants in heterozygous state generally exhibit incomplete penetrance and act as genetic risk factors. Homozygous GBA1 variants, including the p.T75del and c.115+1G>A mutations have been reported to cause Gaucher disease [37–40]. We found these two variants in a heterozygous state in one case and one control in AoU. GBA1 p.T75del was found in individuals of African ancestry, and GBA1 c.115+1G>A was found in individuals of European ancestry in both a case and a control. The GBA1 c.115+1G>A variant was also found in nine European controls in the UKB cohort. Thirteen additional heterozygous variants in GBA1 — p.R502C, p.A495P, p.L483R, p.D448H, p.E427X, p.G416S, p.N409S, p.R398X, p.R296Q, p.G241R, p.N227S, p.S212X, and p.R159W — were identified in our study, and have been reported as disease-causing for Gaucher disease in homozygous state. Three variants in GRN, including two loss of function variants (including p.Q130fs and p.Y294X) and one splicing variant (c.708+6_708+9del), have been previously reported to cause FTD, FTLD, and neurodegenerative disease [37,41–55]. Each of these 16 variants were found in several control individuals (Supplementary Table 4).

Genetic-phenotypic correlations provide valuable clinical insights

Clinical data for the identified variants are summarized in Supplementary Tables 5 and 6. Here, we briefly explain the main findings.

The GRN p.R493X variant is this gene’s most reported pathogenic mutation. This variant has been associated with several types of dementia, including FTD, FTLD, primary progressive aphasia, AD, and corticobasal degeneration. It is known to be more frequently identified among FTD cases, particularly in early-onset forms [56]. In one study investigating the genetics underlying disease etiology in 1,118 DLB patients, this variant was reported in a single case, presenting a wide range of neurological phenotypes that could not lead to a conclusive diagnosis. Severe dementia, parkinsonism, and visual hallucinations suggested a clinical diagnosis of AD or mixed vascular dementia. However, the final neuropathological diagnosis was suggested to be AD, DLB, and argyrophilic grain disease [57]. We identified this variant in four European AD patients, three of whom presented with early onset in their fifties. Interestingly, we also identified this variant in a DLB patient in her early 60s. Neuropathological data and McKeith criteria [58] strongly supported a diagnosis of DLB in this patient. Although this variant has been widely reported across different types of dementia, our finding is the first report of this variant in DLB with a McKeith criteria of “high likelihood of DLB,” expanding the etiological spectrum of GRN variation (Supplementary Table 5).

GRN p.C222Y was previously reported in a familial AD case from Latin American (Caribbean Hispanic) ancestry [59,60]. While the AAO for this patient was not reported, the mean AAO for the cohorts under study was 56.9 years (SD = 7.29), with a range between 40–73 years. In our study, we identified this variant in an individual of American Admixed ancestry with dementia in his late 40s and a disease duration of 11 years to date. This finding reinforces the role of this variant in early-onset disease.

There are several other interesting findings regarding variants in GRN. The GRN c.708+1G>A variant was previously reported in several FTD, FTLD, and corticobasal syndrome (CBS) cases, mostly early-onset [55,61]. We identified this variant in two European AD cases, both diagnosed in their 70s, marking the first report of this variant in late-onset Alzheimer’s disease (LOAD). The GRN p.P166fsX variant was previously reported in an early-onset behavioral variant FTD case [62]. In our study, we identified this variant in a European dementia case diagnosed in her mid 70s with a disease duration of 8 years to date. The GRN p.R418X variant is identified in the literature in two cases of FTLD with ubiquitin-positive inclusions (FTLD-U) with an AAO of 49 and 60 years [63]. We identified this variant in a European dementia case in her early 70s. Both findings represent the first report of these variants in late-onset dementia.

PSEN1 R269H is a known pathogenic variant causing early-onset Alzheimer’s disease (EOAD) [64,65]. However, it has been previously reported in only two LOAD cases [66,67]. In our study, we identified this variant in European and African Admixed ancestries in a total of 12 cases (eight AD and four related dementias), six of which were early-onset (≤65 years) and six were late-onset (>65 years). This finding underscores the potential for PSEN1 p.R269H to contribute to LOAD with reduced penetrance. Additionally, one EOAD case that presented with hallucinations [68] and another that manifested a behavioral presentation [69] have been reported to carry this variant. In this study, we identified PSEN1 p.R269H in one FTD patient in the 100KGP cohort, marking the first report of this variant in FTD.

MAPT p.R406W has been reported in several familial cases of FTD with parkinsonism, all with early onset [70]. There are only two articles related to this variant in AD. The first describes a family with AD-like symptoms, with an average AAO of 61 years [71], and the other reports a familial AD case with an AAO of 50 years [72]. In our study, we identified this variant in nine AD cases, with a mean AAO of 61 years. This finding underscores the role of this variant in EOAD.

Several variants in GBA1, such as p.F298L, p.V230G, p.W223R, and p.P198L, have been previously reported in Gaucher disease patients. In our study, we identified these variants in heterozygous state in one AD case and five dementia cases, all with late onset. GBA1 p.W223R was found in one AD case of Complex Admixture History ancestry. GBA1 mutations are known to confer an increased risk for dementia in PD and DLB. Notably, they have not been previously suggested to contribute to AD.

Similarly, APP p.E693Q has been reported in a few AD cases. In our study, we identified it in a related dementia case and no controls. This finding suggests that this variant may also be implicated in other types of dementia.

Several known variants identified in this study confirm previous findings related to disease type and onset. For example, the APP p.V717L variant has been reported in numerous AD cases, primarily in early-onset forms [73,74]. In our study, we identified this variant in two cases of EOAD with AAO ranges of 51-55 years and 56-60 years, respectively. Additional examples are reported in Supplementary Tables 5 and 6.

In AoU, the SNCA p.Q99R variant was found in a female patient diagnosed in her late 60s with unspecified dementia without behavioral disturbance. In ADSP, the variant was identified in a male patient diagnosed with pure AD in his early 70s. SNCA p.P90H and p.A91S were found in two males in their late 70s in the UKB cohort. All four patients were of European ancestry. Previously reported mutations in SNCA are known to cause early-onset PD and DLB [75,76]. The mean AAO in patients carrying SNCA mutations in this study is 72.75 years. These data suggest that these variants may not be disease-causing but could represent rare risk factors despite their absence in controls and the replication of p.Q99R across datasets.

Novel variants found in this study that may potentially be associated with early-onset dementia include: p.L597W, p.V375I, p.L364F, p.A209T, p.D460N, p.R409C, and p.V227L variants in APP; p.R54X and p.M457V in PSEN1; p.H169R, p.D320N, and p.G349R in PSEN2; p.R556C and p.V28fs in GRN; p.G332LfsX64 and p.G701R in MAPT; p.G103D and p.A42T in GBA1; and TREM2 p.W44X. Among these variants, APP p.L364F and PSEN1 p.R54X were found in vascular dementia cases with AAO ranges of 41-45 years and 46-50 years, respectively. Additionally, PSEN2 p.D320N was found in an FTD case with an AAO in his mid-50s. Another notable finding is the identification of GRN p.R556C in a dementia case with an AAO in her mid-30s.

APOE drives different population-attributable risk for Alzheimer’s disease and related dementias

The summary of our findings on ancestry-specific effects of APOE on AD/ADRDs is depicted in Figure 4, Table 5, and Supplementary Figure 3. In AoU, UKB, and 100KGP, the APOE ε4/ε4 genotype exhibits a higher frequency among both AD patients and control individuals of African and African Admixed ancestries compared to Europeans. Related dementia patients show similar results in UKB. In AoU, related dementia cases of African Admixed ancestry show a higher frequency than Europeans, while frequencies are similar between Africans and Europeans, likely due to the limited number of individuals with African ancestry in this dataset. In ADSP, the frequencies of this genotype among AD patients are similar across the three ancestries. Among control individuals in ADSP, APOE ε4/ε4 is more frequent in African Admixed and African ancestries than in Europeans, as previously reported [77]. Notably, the APOE ε4/ε4 genotype was absent from African and African Admixed DLB cases and controls in the AMP PD dataset. The frequency of APOE ε4/ε4 in Europeans was higher in cases compared to controls in AMP PD.

• Download figure
• Open in new tab

Figure 4. Proportions of APOE ε4/ε4 across 11 genetic ancestries in Alzheimer’s disease, related dementias, and controls in all datasets.

When combining results across all datasets, the frequency of APOE ε4/ε4 in African and African Admixed AD patients is still higher than in Europeans, but the values are not significantly different. However, the frequency of APOE ε4/ε4 in control individuals of African and African Admixed ancestries was found to be substantially higher than in controls of European ancestry. Additionally, the frequency of APOE ε4/ε4 in Finnish individuals was found to be higher in AD cases and lower in controls compared to Europeans.

Disease-modifying variants in APOE ε4 carriers modulate Alzheimer’s and dementia risk across different ancestries

The summary of our findings for the frequencies of protective and disease-modifying variants under study, alongside APOE genotypes across all five datasets, is depicted in Supplementary Tables 7–11. The proportions of individuals carrying APOE ε4 homozygous or heterozygous genotypes alongside protective or disease-modifying variants, within the total population, total ε4/ε4 carriers, and total ε4 carriers across each ancestry, combined across all biobanks, in AD, related dementias, and controls are reported in Figure 5, Supplementary Figure 4 and Supplementary Table 12. Summaries of our findings for all the assessed models in APOE ε4, ε4ε4, and ε3ε3 are shown in Figure 6, Table 6 and Supplementary Tables 13–22.

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 5. Proportions of individuals carrying both APOE ε4 and protective or disease- modifying variants across 11 genetic ancestries in Alzheimer’s disease, related dementias, and controls in all datasets.

(A) SNP frequencies for each variant within each ancestry relative to the total number of ε4 carriers per ancestry across all datasets. (B) AD-to-control allele frequency ratios (left) and related dementia-to-control ratios (right). Warmer colors represent higher frequencies in cases versus controls, while cooler colors represent higher frequencies in controls versus cases, with dark blue (N/A) representing variants not present in either cases or controls.

• Download figure
• Open in new tab

Figure 6. Upset plot showing protective, conditional, and interaction models across multiple ancestries.

The Y-axis represents each ancestry population with a large enough sample size, and the X-axis represents the six protective/disease-modifying variants. The color bar shows the magnitude of effects as log of the odds ratio (beta value) and directionality, with red color denoting negative directionality, and blue colors denoting positive directionality.

In brief, we observe higher frequencies of individuals carrying APOE:rs449647-T, 19q13.31:rs10423769-A, APP:rs466433-G, or APP:rs364048-C protective variant alleles alongside either one or two copies of APOE ε4 among African and African Admixed ancestries compared to Europeans in AD, related dementias, and controls. Of note, carriers of APOE:rs449647-T and 19q13.31:rs10423769-A are particularly noteworthy because APOE:rs449647-T displays the highest frequency among these ancestries, and the ratio of frequencies for 19q13.31:rs10423769-A in both African and African Admixed ancestries compared to Europeans is substantially higher than the other protective/disease-modifying variants investigated across all three cohorts. In individuals of African ancestry, 19q13.31:rs10423769-A was found to have a higher frequency in controls compared to both AD and related dementia cases among APOE ε4 homozygous or heterozygous carriers. In contrast, APOE:rs449647-T was found to have a lower frequency in controls compared to AD cases among APOE ε4 homozygous or heterozygous carriers in African ancestry but showed a higher frequency in controls carrying APOE ε4/ε4 versus cases in European populations (Supplementary Table 12).

The combination of TOMM40:rs11556505-T with either homozygous or heterozygous APOE ε4 was observed to have a higher frequency in Europeans and a lower frequency in Africans compared to most other ancestries across all three phenotypes. Additionally, the combination of NOCT:rs13116075-G and APOE ε4 homozygous or heterozygous was found to have a higher frequency in individuals of European and African Admixed ancestry versus Africans, in AD cases as compared to controls.

The protective model shows a modifying effect of APOE:rs449647-T in European, African, and Ashkenazi Jewish ancestries as well as a modifying effect of TOMM40:rs11556505-T in European, American Admixed, Ashkenazi Jewish, African Admixed, and individuals of Complex Admixture History. The R² model indicates that these variants are not in linkage disequilibrium with the APOE risk variants rs429358 and rs7412 (Table 6).

Significant interactions were found between APOE ε4 and the following variants: 19q13.31:rs10423769-A in Africans; NOCT:rs13116075-G in both African and African Admixed populations; CASS4:rs6024870-A in the Complex Admixed History group; LRRC37A:rs2732703- G in the American Admixed ancestry; APOE:rs449647-T in European and African Admixed ancestries; and TOMM40:rs11556505-T in Europeans. In APOE ε4/ε4 carriers, the interaction with APOE:rs449647-T was found to be significant in American Admixed and African Admixed populations, while TOMM40:rs11556505-T was significant in the European ancestry (Table 6).

The interaction model in APOE ε3/ε3 shows no significant p-value for 19q13.31:rs10423769-A in Africans, NOCT:rs13116075-G in African Admixed ancestry, CASS4:rs6024870-A in Complex Admixed History, and LRRC37A:rs2732703-G in American Admixed ancestry, but highly significant p-values for APOE:rs449647-T and TOMM40:rs11556505-T in European and NOCT:rs13116075-G in Africans with opposite directional effects compared to APOE ε4 carriers. These data confirm the role of these variants in modulating the effect of APOE ε4 in AD risk (Table 6).